Preserving the Ocular Surface: Practice Pearls—Part IV
This activity is supported by educational grants from Alcon Laboratories, Inc.; Allergan, Inc.; Bausch + Lomb; Kala Pharmaceuticals; and Shire.
Pretest
Please try again. The questions you answered incorrectly are highlighted in red below.
The correct answer is D.
Rationale: Although the TearLab Osmolarity System can determine whether the patient has dry eye, it cannot determine what type of dry eye disease is present. It is associated with a high degree of specificity but variable sensitivity.
The correct answer is C.
Rationale: Approximately 60% of patients in the KPI-121 arm had a greater than 1-unit improvement in conjunctival hyperemia at days 15 and 29. This was approximately 20% to 25% higher than the vehicle arm.
The correct answer is B.
Rationale: Lifitegrast is a lymphocyte function–associated antigen-1 (LFA-1) antagonist, which prevents LFA-1 binding to intercellular adhesion molecule-1 (ICAM-1).
The correct answer is B.
Rationale: The patients who benefit the most from loteprednol etabonate 0.5% therapy are those with dry eye with an inflammatory component. This medication is contraindicated in patients with viral or fungal keratitis. It may raise IOP.